# Pelthos Therapeutics Inc.: financial statements, quarterly

PTHS · NYSE · CIK 1919246 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pths.md) · [Financials](/companies/pths/financials.md) · [Filings](/companies/pths/filings.md) · [Insiders](/companies/pths/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pths/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001919246-26-000111.md) | [0.0](/filings/0001919246-26-000113.md) | [0.3](/filings/0001753926-25-001764.md) | [16.5 d](/filings/0001919246-26-000013.md) | [10.9](/filings/0001919246-26-000111.md) | [15.6](/filings/0001919246-26-000113.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001919246-26-000111.md) | [0.0](/filings/0001919246-26-000113.md) | [2.3](/filings/0001753926-25-001764.md) | [1.7 d](/filings/0001919246-26-000013.md) | [1.7](/filings/0001919246-26-000111.md) | [3.6](/filings/0001919246-26-000113.md) |
| Research and development | $m | [0.0](/filings/0001753926-24-001883.md) | [2.3 d](/filings/0001753926-25-000503.md) | [0.5](/filings/0001753926-25-000790.md) | [0.0](/filings/0001753926-25-001326.md) | [0.4](/filings/0001753926-25-001764.md) | [0.3 d](/filings/0001919246-26-000013.md) | [0.2](/filings/0001919246-26-000111.md) | [0.5](/filings/0001919246-26-000113.md) | [0.1](/filings/0001753926-25-001764.md) | [0.4 d](/filings/0001919246-26-000013.md) | [0.2](/filings/0001919246-26-000111.md) | [0.6](/filings/0001919246-26-000113.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | [1.6](/filings/0001753926-25-001764.md) | [1.5 d](/filings/0001919246-26-000013.md) | [1.6](/filings/0001919246-26-000111.md) | [2.7](/filings/0001919246-26-000113.md) | [19.6](/filings/0001753926-25-001764.md) | [18.5 d](/filings/0001919246-26-000013.md) | [21.1](/filings/0001919246-26-000111.md) | [27.7](/filings/0001919246-26-000113.md) |
| Operating income | $m | [(1.3)](/filings/0001753926-24-001883.md) | [(3.9) d](/filings/0001753926-25-000503.md) | [(1.9)](/filings/0001753926-25-000790.md) | [(1.8)](/filings/0001753926-25-001326.md) | [(2.0)](/filings/0001753926-25-001764.md) | [(1.8) d](/filings/0001919246-26-000013.md) | [(1.8)](/filings/0001919246-26-000111.md) | [(3.2)](/filings/0001919246-26-000113.md) | [(15.4)](/filings/0001753926-25-001764.md) | [(12.0) d](/filings/0001919246-26-000013.md) | [(13.1)](/filings/0001919246-26-000111.md) | [(17.3)](/filings/0001919246-26-000113.md) |
| Interest expense | $m | not reported | not reported | [0.0](/filings/0001753926-25-000790.md) | not reported | [0.0](/filings/0001753926-25-001764.md) | [0.1 d](/filings/0001919246-26-000013.md) | [0.0](/filings/0001753926-25-000790.md) | [0.2](/filings/0001919246-26-000113.md) | [1.3](/filings/0001753926-25-001764.md) | [1.3 d](/filings/0001919246-26-000013.md) | [2.4](/filings/0001919246-26-000111.md) | [2.4](/filings/0001919246-26-000113.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001919246-26-000111.md) | [0.0](/filings/0001919246-26-000113.md) | [(0.5)](/filings/0001753926-25-001764.md) | [(6.9) d](/filings/0001919246-26-000013.md) | [0.0](/filings/0001919246-26-000111.md) | [0.0](/filings/0001919246-26-000113.md) |
| Net income | $m | [(1.4)](/filings/0001753926-24-001883.md) | [(4.0) d](/filings/0001753926-25-000503.md) | [(2.6)](/filings/0001753926-25-001764.md) | [(1.8)](/filings/0001753926-25-001764.md) | [(1.7)](/filings/0001753926-25-001764.md) | [(1.9) d](/filings/0001919246-26-000013.md) | [(2.0)](/filings/0001919246-26-000113.md) | [(3.4)](/filings/0001919246-26-000113.md) | [(16.2)](/filings/0001753926-25-001764.md) | [(21.7) d](/filings/0001919246-26-000013.md) | [(25.1)](/filings/0001919246-26-000113.md) | [(23.4)](/filings/0001919246-26-000113.md) |
| Diluted EPS | $ per share | not reported | not reported | [(0.55)](/filings/0001753926-25-000790.md) | [(3.07)](/filings/0001753926-25-001326.md) | [(2.93)](/filings/0001753926-25-001764.md) | not reported | [(3.21)](/filings/0001919246-26-000111.md) | [(5.29)](/filings/0001919246-26-000113.md) | [(5.30)](/filings/0001753926-25-001764.md) | not reported | [(7.57)](/filings/0001919246-26-000111.md) | [(6.62)](/filings/0001919246-26-000113.md) |
| Basic EPS | $ per share | [(1.44)](/filings/0001753926-24-001883.md) | not reported | [(0.55)](/filings/0001753926-25-000790.md) | [(3.07)](/filings/0001753926-25-001326.md) | [(2.93)](/filings/0001753926-25-001764.md) | not reported | [(3.21)](/filings/0001919246-26-000111.md) | [(5.29)](/filings/0001919246-26-000113.md) | [(5.30)](/filings/0001753926-25-001764.md) | not reported | [(7.57)](/filings/0001919246-26-000111.md) | [(6.62)](/filings/0001919246-26-000113.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [0.1](/filings/0001753926-24-001883.md) | [3.8](/filings/0001753926-24-000976.md) | [2.4](/filings/0001753926-24-001423.md) | [1.3](/filings/0001753926-24-001883.md) | [0.5](/filings/0001919246-26-000013.md) | [0.1](/filings/0001919246-26-000111.md) | [0.1](/filings/0001919246-26-000113.md) | [14.2](/filings/0001753926-25-001764.md) | [18.0](/filings/0001919246-26-000113.md) | [32.0](/filings/0001919246-26-000111.md) | [24.2](/filings/0001919246-26-000113.md) |
| Current assets | $m | not reported | [0.1](/filings/0001753926-25-000503.md) | [4.0](/filings/0001753926-24-000976.md) | [2.6](/filings/0001753926-24-001423.md) | [2.1](/filings/0001753926-24-001883.md) | [1.4](/filings/0001919246-26-000013.md) | [0.9](/filings/0001753926-25-000790.md) | [0.8](/filings/0001753926-25-001326.md) | [49.8](/filings/0001753926-25-001764.md) | [53.4](/filings/0001919246-26-000113.md) | [69.8](/filings/0001919246-26-000111.md) | [63.4](/filings/0001919246-26-000113.md) |
| Total assets | $m | not reported | [0.1](/filings/0001753926-25-000503.md) | [4.0](/filings/0001753926-24-000976.md) | [2.6](/filings/0001753926-24-001423.md) | [2.1](/filings/0001753926-24-001883.md) | [1.4](/filings/0001919246-26-000013.md) | [0.9](/filings/0001753926-25-000790.md) | [0.8](/filings/0001753926-25-001326.md) | [126](/filings/0001753926-25-001764.md) | [130](/filings/0001919246-26-000113.md) | [145](/filings/0001919246-26-000111.md) | [137](/filings/0001919246-26-000113.md) |
| Current liabilities | $m | not reported | [6.5](/filings/0001753926-25-000503.md) | [2.9](/filings/0001753926-24-000976.md) | [2.8](/filings/0001753926-24-001423.md) | [3.6](/filings/0001753926-24-001883.md) | [4.1](/filings/0001919246-26-000013.md) | [5.1](/filings/0001753926-25-000790.md) | [7.3](/filings/0001753926-25-001326.md) | [24.8](/filings/0001753926-25-001764.md) | [26.0](/filings/0001919246-26-000113.md) | [25.0](/filings/0001919246-26-000111.md) | [32.0](/filings/0001919246-26-000113.md) |
| Total liabilities | $m | not reported | [6.5](/filings/0001753926-25-000503.md) | [2.9](/filings/0001753926-24-000976.md) | [2.8](/filings/0001753926-24-001423.md) | [3.6](/filings/0001753926-24-001883.md) | [4.1](/filings/0001919246-26-000013.md) | [5.1](/filings/0001753926-25-000790.md) | [7.3](/filings/0001753926-25-001326.md) | [68.2](/filings/0001753926-25-001764.md) | [91.5](/filings/0001919246-26-000113.md) | [126](/filings/0001919246-26-000111.md) | [139](/filings/0001919246-26-000113.md) |
| Shareholders' equity | $m | [(5.9)](/filings/0001753926-24-001883.md) | [(6.4)](/filings/0001919246-26-000013.md) | [1.1](/filings/0001753926-25-001764.md) | [(0.2)](/filings/0001753926-25-001764.md) | [(1.4)](/filings/0001753926-25-001764.md) | [(2.7)](/filings/0001919246-26-000113.md) | [(4.2)](/filings/0001919246-26-000113.md) | [(6.5)](/filings/0001919246-26-000113.md) | [58.3](/filings/0001753926-25-001764.md) | [38.9](/filings/0001919246-26-000113.md) | [19.3](/filings/0001919246-26-000113.md) | [(1.5)](/filings/0001919246-26-000113.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(0.3) d](/filings/0001753926-24-001883.md) | [(0.4) d](/filings/0001753926-25-000503.md) | [(2.0)](/filings/0001753926-25-000790.md) | [(3.0) d](/filings/0001753926-25-001326.md) | [(0.2) d](/filings/0001753926-25-001764.md) | [(0.7) d](/filings/0001919246-26-000013.md) | [(0.6)](/filings/0001919246-26-000111.md) | [(0.4) d](/filings/0001919246-26-000113.md) | [(15.3) d](/filings/0001753926-25-001764.md) | [(6.3) d](/filings/0001919246-26-000013.md) | [(13.1)](/filings/0001919246-26-000111.md) | [(7.7) d](/filings/0001919246-26-000113.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001919246-26-000111.md) | [0.0 d](/filings/0001919246-26-000113.md) | not reported | not reported | [0.2](/filings/0001919246-26-000111.md) | [0.0 d](/filings/0001919246-26-000113.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [4,691](/filings/0001753926-25-000790.md) | [577](/filings/0001753926-25-001326.md) | [579](/filings/0001753926-25-001764.md) | [613](/filings/0001919246-26-000111.md) | [652](/filings/0001919246-26-000113.md) | [3,061](/filings/0001753926-25-001764.md) | [3,312](/filings/0001919246-26-000111.md) | [3,539](/filings/0001919246-26-000113.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 3,828,469 at 2026-08-10, from the cover of the [10-Q filed 2026-08-13](/filings/0001919246-26-000113.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.